Compare Mesoblast Limited (MESO) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Under Armour Inc Class A — how do they compare? Mesoblast Limited trades at $14.24 (market cap $1.75B), while Under Armour Inc Class A trades at $4.96 (market cap $2.07B). The key difference: Under Armour Inc Class A is the larger of the two by market cap, and Mesoblast Limited is more actively traded (239,027 versus 12,050,442). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Under Armour Inc Class A for 99 Days on average.
| MESO | UAA | |
|---|---|---|
Market Cap | $1.75B | $2.07B |
Volume | 239,027 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $8.14 |
52-Week Low | $13.19 | $4.17 |
Typical Hold Time | 15 Days | 99 Days |
Enterprise Value | $1.83B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Under Armour (UAA) trades at $4.93, up 2.28% on the day, with a mixed technical outlook showing a bullish moving average signal but a neutral oscillator stance. The company reported a net loss of $201.27M in 2025, with revenue declining to $5.16B, though recent quarterly earnings have beaten expectations. Analyst consensus is a 'Hold' with a $5.79 price target, while news highlights the company's focus on product simplification and margin improvement amid softer demand.
The outlook remains challenging due to persistent revenue weakness and negative profitability, but cost discipline and international growth offer potential stabilization. Key risks include execution of the turnaround plan and competitive pressures. The stock presents a speculative opportunity for investors betting on a successful brand transformation, but requires careful risk assessment given the current financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
